Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

(2021) Ronan J. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

(2021) Ian Chau et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

(2020) Jing Huang et al.   LANCET ONCOLOGY

Immunotherapy to treat malignancy in patients with pre-existing autoimmunity

(2020) Patrick Boland et al.   Journal for ImmunoTherapy of Cancer

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

(2020) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

(2020) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

(2020) Jayesh Desai et al.   Journal for ImmunoTherapy of Cancer

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

(2020) Lin Shen et al.   Journal for ImmunoTherapy of Cancer

154P Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)

(2020) Y. Chao et al.   ANNALS OF ONCOLOGY

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

(2020) Takashi Kojima et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Esophageal cancer: Risk factors, genetic association, and treatment

(2018) Fang-Liang Huang et al.   Asian Journal of Surgery

The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

(2018) Tong Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Global time trends in the incidence of esophageal squamous cell carcinoma

(2018) Qiao-Li Wang et al.   Clinical Epidemiology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

(2018) K Muro et al.   ANNALS OF ONCOLOGY

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) F. Lordick et al.   ANNALS OF ONCOLOGY

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

(2013) Hugo E R Ford et al.   LANCET ONCOLOGY